buyModerate cluster of 5
Benjamin J. Zeskind bought $50k of IMRX
PRESIDENT AND CEO at Immuneering Corp. 21,000 shares at an average of $2.39, traded Jun 18, 2025, filed Jun 20, 2025.
Conviction score
42Value
$50k
21,000 shares
Holdings after
2,302,852
+1% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- +7Trade size$50k at market
- -5Relative to holdingsUnder 1% of holdings (0.9%)
- 0Price contextNo price history yet
- +15Cluster5 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001790340-25-000081, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 18, 2025 | POpen-market purchase Class A Common Stock | +21,000 | $2.39 | $50k | 2,302,852 | Jun 20, 2025 |
Related signals
Other insiders at Immuneering Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 47Moderate | Immuneering Corp | Thomas J. Schall director | $35k 9,500 shares | +22% | |
| 36Weak | Immuneering Corp | Harold Eugene Brakewood Chief Business Officer | $4,804 1,900 shares | +49% | |
| 36Weak | Immuneering Corp | Brett Matthew Hall CHIEF SCIENTIFIC OFFICER | $35k 13,422 shares | +4% | |
| 44Moderate | Immuneering Corp | Peter Feinberg director | $63k 25,000 shares | +22% | |
| 49Moderate | Immuneering Corp | Thomas J. Schall director | $89k 40,485 shares | +1396% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.